A detailed study on Biosimilars/Follow-on-Biologics market complied by primary and secondary research and validated by industry experts. If you are planning to understand the Biosimilars/Follow-on-Biologics market in and out, then this is a must have report. You will also get free analyst support with this report.
Biosimilars/Follow-on-Biologics market is one of the markets, where investors have shown great interest. As per the research the market is expected to grow with a CAGR of XX% in coming years. Biosimilars/Follow-on-Biologics Market Sizes, Shares, Prices, Trends, and Forecasts have been derived from an in-depth study of the current scenarios in the. This report is based on both value and volume (Where applicable).
*This is a smart report which can be customized according to your need.
Highlights Of The Report:
1. Market structure and projections for the coming years.
2. Drivers, restraints, opportunities, and current trends.
3. Historical data and forecast.
4. Estimations for the forecast period between 2020 and 2026.
5. Developments and trends in the market.
6. By Type:
Human growth hormone
Erythropoietin
Monoclonal antibodies
Insulin
Interferon
7. By Application:
Blood disorders
Oncology diseases
Chronic and autoimmune diseases
Growth hormone deficiencies
Others
8. Market scenario by region, sub-region, and country.
9. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
10. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
11. Government Policies, Macro & Micro economic factors are also included in the report.
Overview of the regional outlook of the market:
- The report offers information about the regions in the market, which is further divided into sub-regions and countries.
- In addition to the market share of each country and sub-region, information regarding lucrative opportunities is included in this chapter of the report.
- Share and market growth rate of each region, country, and sub-region are mentions in this chapter of the report during the estimated time period.
Companies profiled in this report:
1) Novartis
2) Synthon Pharmaceuticals
3) Teva Pharmaceutical Industries
4) LG Life Sciences
5) Celltrion
6) Biocon
7) Hospira
8) Merck Group
9) Biogen idec, Inc.
10) Genentech (Roche Group)12345
*Additional companies can be added in Biosimilars/Follow-on-Biologics market report as a part of free customization. Feel free to get in touch with our research analyst.
This chapter of the report comprises various key companies operating in the global market. This helps the reader understand the competitive landscape, including the strategies adopted by the players to stay in the competitive market.
- Market Share
- Company Profile
- Business Information
- SWOT Analysis
- Strategies
Reasons To Purchase The Biosimilars/Follow-on-Biologics Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
- Moreover, we provide data support, in the excel format, and 1-year free analyst support.
Frequently Asked Questions?
Biosimilars are generic versions of biologic drugs, which are medications derived from living organisms. Follow-on biologics are similar to biosimilars, but they are products that have been modified after they were initially developed as biosimilars.
Some of the major companies in the biosimilars/follow-on-biologics market are Novartis, Synthon Pharmaceuticals, Teva Pharmaceutical Industries, LG Life Sciences, Celltrion, Biocon, Hospira, Merck Group, Biogen idec, Inc..
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Biosimilars/Follow-on-Biologics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Biosimilars/Follow-on-Biologics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Biosimilars/Follow-on-Biologics Market - Supply Chain
4.5. Global Biosimilars/Follow-on-Biologics Market Forecast
4.5.1. Biosimilars/Follow-on-Biologics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Biosimilars/Follow-on-Biologics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Biosimilars/Follow-on-Biologics Market Absolute $ Opportunity
5. Global Biosimilars/Follow-on-Biologics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Biosimilars/Follow-on-Biologics Market Size and Volume Forecast by Type
5.3.1. Human growth hormone
5.3.2. Erythropoietin
5.3.3. Monoclonal antibodies
5.3.4. Insulin
5.3.5. Interferon
5.3.6. Granulocyte-Colony Stimulating Factor
5.3.7. Peptide
5.3.8. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Biosimilars/Follow-on-Biologics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Biosimilars/Follow-on-Biologics Market Size and Volume Forecast by Application
6.3.1. Blood disorders
6.3.2. Oncology diseases
6.3.3. Chronic and autoimmune diseases
6.3.4. Growth hormone deficiencies
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Biosimilars/Follow-on-Biologics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Biosimilars/Follow-on-Biologics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Biosimilars/Follow-on-Biologics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Biosimilars/Follow-on-Biologics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Biosimilars/Follow-on-Biologics Demand Share Forecast, 2019-2026
9. North America Biosimilars/Follow-on-Biologics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Biosimilars/Follow-on-Biologics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Biosimilars/Follow-on-Biologics Market Size and Volume Forecast by Application
9.4.1. Blood disorders
9.4.2. Oncology diseases
9.4.3. Chronic and autoimmune diseases
9.4.4. Growth hormone deficiencies
9.4.5. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Biosimilars/Follow-on-Biologics Market Size and Volume Forecast by Type
9.7.1. Human growth hormone
9.7.2. Erythropoietin
9.7.3. Monoclonal antibodies
9.7.4. Insulin
9.7.5. Interferon
9.7.6. Granulocyte-Colony Stimulating Factor
9.7.7. Peptide
9.7.8. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Biosimilars/Follow-on-Biologics Demand Share Forecast, 2019-2026
10. Latin America Biosimilars/Follow-on-Biologics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Biosimilars/Follow-on-Biologics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Biosimilars/Follow-on-Biologics Market Size and Volume Forecast by Application
10.4.1. Blood disorders
10.4.2. Oncology diseases
10.4.3. Chronic and autoimmune diseases
10.4.4. Growth hormone deficiencies
10.4.5. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Biosimilars/Follow-on-Biologics Market Size and Volume Forecast by Type
10.7.1. Human growth hormone
10.7.2. Erythropoietin
10.7.3. Monoclonal antibodies
10.7.4. Insulin
10.7.5. Interferon
10.7.6. Granulocyte-Colony Stimulating Factor
10.7.7. Peptide
10.7.8. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Biosimilars/Follow-on-Biologics Demand Share Forecast, 2019-2026
11. Europe Biosimilars/Follow-on-Biologics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Biosimilars/Follow-on-Biologics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Biosimilars/Follow-on-Biologics Market Size and Volume Forecast by Application
11.4.1. Blood disorders
11.4.2. Oncology diseases
11.4.3. Chronic and autoimmune diseases
11.4.4. Growth hormone deficiencies
11.4.5. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Biosimilars/Follow-on-Biologics Market Size and Volume Forecast by Type
11.7.1. Human growth hormone
11.7.2. Erythropoietin
11.7.3. Monoclonal antibodies
11.7.4. Insulin
11.7.5. Interferon
11.7.6. Granulocyte-Colony Stimulating Factor
11.7.7. Peptide
11.7.8. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Biosimilars/Follow-on-Biologics Demand Share, 2019-2026
12. Asia Pacific Biosimilars/Follow-on-Biologics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Biosimilars/Follow-on-Biologics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Biosimilars/Follow-on-Biologics Market Size and Volume Forecast by Application
12.4.1. Blood disorders
12.4.2. Oncology diseases
12.4.3. Chronic and autoimmune diseases
12.4.4. Growth hormone deficiencies
12.4.5. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Biosimilars/Follow-on-Biologics Market Size and Volume Forecast by Type
12.7.1. Human growth hormone
12.7.2. Erythropoietin
12.7.3. Monoclonal antibodies
12.7.4. Insulin
12.7.5. Interferon
12.7.6. Granulocyte-Colony Stimulating Factor
12.7.7. Peptide
12.7.8. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Biosimilars/Follow-on-Biologics Demand Share, 2019-2026
13. Middle East & Africa Biosimilars/Follow-on-Biologics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Biosimilars/Follow-on-Biologics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Biosimilars/Follow-on-Biologics Market Size and Volume Forecast by Application
13.4.1. Blood disorders
13.4.2. Oncology diseases
13.4.3. Chronic and autoimmune diseases
13.4.4. Growth hormone deficiencies
13.4.5. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Biosimilars/Follow-on-Biologics Market Size and Volume Forecast by Type
13.7.1. Human growth hormone
13.7.2. Erythropoietin
13.7.3. Monoclonal antibodies
13.7.4. Insulin
13.7.5. Interferon
13.7.6. Granulocyte-Colony Stimulating Factor
13.7.7. Peptide
13.7.8. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Biosimilars/Follow-on-Biologics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Biosimilars/Follow-on-Biologics Market: Market Share Analysis
14.2. Biosimilars/Follow-on-Biologics Distributors and Customers
14.3. Biosimilars/Follow-on-Biologics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novartis
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Synthon Pharmaceuticals
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Teva Pharmaceutical Industries
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. LG Life Sciences
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Celltrion
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Biocon
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Hospira
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Merck Group
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Biogen idec, Inc.
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Genentech (Roche Group)
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
1
